In addition, pharmacodynamic experiments confirmed that the combination of SL@BRNPs with an anti-PD-L1 antibody greatly prevented primary BC cells, improving the CD8 + T cell surface area and CD8+ T cells/Tregs proportions in a tumor. This evidence concerns the gene CD8A and breast cancer.